戻る Agenda
Session 6BC: What, Where, and How: Biomarkers Inform Disease Targets, Biodistribution, and Function of Oligonucleotide Therapeutics
Session Chair(s)
Aimee L. Jackson, PhD
Chief Scientific Officer
Atalanta Therapeutics, United States
This session will present preclinical and clinical data on the identification and validation of biomarkers for oligonucleotide therapeutics. Discussions will include methods to identify pharmacodynamic biomarkers, use of biomarkers to define PK/PD and dose-response relationships, the application of biomarkers to establish mechanistic proof-of-concept and guide dose optimization, and how biomarkers can inform disease status and patient enrichment.
Learning Objective :
Speaker(s)
Session Co-Chair
Imran Khan, PhD
FDA, United States
Pharmacologist, OMPT, OND, ODEI, DPP, CDER
Translating PD Biomarkers from Preclinical Studies to Clinical Trials: MRG-106, an Oligonucleotide Inhibitor of miR-155, Coordinately Regulates Multiple Survival Pathways to Reduce Cellular Proliferation, and Survival in Cutaneous T-Cell Lymphoma
Aimee L. Jackson, PhD
Atalanta Therapeutics, United States
Chief Scientific Officer
Translating PD Biomarkers from Preclinical Studies to Clinical Trials: MRG-201, an Oligonucleotide Mimic of miR-29, Inhibits Collagen Expression, and Reduces Fibroplasia in Cutaneous Wounds
Corrie L Gallant-Behm, PhD
Miragen Therapeutics, Inc., United States
Research Scientist III
Use of Biomarkers in the Development of RNAi Therapeutics
William Querbes, PhD
Alnylam Pharmaceuticals, United States
Director, Research
Panel Discussion
All Session Speakers, United States